Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BRII-179

Phase 2Biologic

BBrii Biosciences Limited

BRII-179 is one of 45 biologic programs targeting Chronic Hepatitis. It is currently in Phase 2.

1

Indications

3

Total Trials

2

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisRecruiting

Chronic HepatitisPhase 2

Recruiting

Competition

Competitive Landscape

81 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

PEG-IFNα

Bepirovirsen

Opdivo

Bristol-Myers Squibb

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Pegylated Interferon Alfa

NA Therapy

AHB-137

AAusper Biopharma Co., Ltd.

Brelovitug

MMirum Pharmaceuticals, Inc.

Azvudine

HHenan Genuine Biotech Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Chronic Hepatitis

NCT06491563

Q3 2027

Phase 2Recruiting

Chronic Hepatitis

NCT06650852

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT06491563·150 enrolled

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting·BBrii Biosciences Limited·Phase 2·NCT06650852·250 enrolled

Hepatitis B, Chronic1 trial

A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Completed·BBrii Biosciences Limited·Phase 2·NCT04749368·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BRII-179. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BRII-179 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BRII-179. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brii Biosciences Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBrii Biosciences Limited

Related News